Managing unwanted immunogenicity of biologicals.

Managing unwanted immunogenicity of biologicals.

Item
http://www.wikidata.org/entity/Q35572412
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesRecent Advances in Application of Pharmacogenomics for BiotherapeuticsB cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.Cellulose nanocrystals: a versatile nanoplatform for emerging biomedical applications.A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseEvaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance.Designing a mutant Candida uricase with improved polymerization state and enzymatic activity.Anticalin® Proteins as Therapeutic Agents in Human Diseases.
P2860

Managing unwanted immunogenicity of biologicals.

Item
http://www.wikidata.org/entity/Q35572412
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Managing unwanted immunogenicity of biologicals.
@ast
Managing unwanted immunogenicity of biologicals.
@en
type
label
Managing unwanted immunogenicity of biologicals.
@ast
Managing unwanted immunogenicity of biologicals.
@en
prefLabel
Managing unwanted immunogenicity of biologicals.
@ast
Managing unwanted immunogenicity of biologicals.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Managing unwanted immunogenicity of biologicals
@en
P2093
P304
P31
P356
10.1016/J.AUTREV.2015.02.007
P433
P478
P50
P577
P698